Varicella-zoster virus (VZV) causes varicella in susceptible individuals, establishes latent infection in neural ganglia and reactivates as herpes zoster. The importance of VZV cellular immunity is illustrated by the severity of varicella in children with T-cell deficiencies. In the studies proposed, new methods employing vaccinia recombinants that express VZV proteins and synthetic peptides that correspond to regions of major VZV proteins will be used analyze the viral protein targets of T- cell immunity during varicella and in longterm naturally acquired or vaccine-induced immunity. Vaccinia recombinants expressing glycoproteins (gp) I, IV and V and immediate early (IE) protein, will provide specific antigens to analyze helper T-cell proliferation and IFN-g production to VZV proteins during acute primary VZV infection and persistent cellular immunity. Helper T-cell epitopes of gp I, IE protein, nucleocapsid proteins (NA) and viral DNA polymerase will de defined with synthetic peptides. Synthetic peptides will help to determine whether a few regions of VZV proteins are predictably recognized by T-cells from individuals of varying HLA types. The kinetics and protein specificity of CTL will be examined during acute varicella using autologous lymphoblastoid cells (LCL) infected with VZV or VZV-vaccinia recombinants as targets. The frequency of memory CTL specific for particular VZV proteins will be assessed b y the limiting dilution cytotoxicity assay. VZV epitopes recognized by CTL will be determined using synthetic peptides to sensitize LCL. The identification of VZV proteins that elicit cellular immunity and of T-cell epitopes for both helper and CTL responses can be used to guide new approaches to VZV immunization. Cell- associated viremia, a critical event during the pathogenesis of primary VZV infection will be investigated further using in situ hybridization with VZV and RNA probes, including probes for immediate early gene 62. Cell-associated viremia in VZV pathogenesis will also be investigated by making viral strains that have been modified by recombinant DNA techniques. Mutant strains of VZV will be developed by inserting E. coli lacZ gene sequences to disrupt VZV gene function recombinant strains will be tested for the effects of insertional mutagenesis upon the capacity to infect PBMC in vitro. The ultimate goal of these experiments will be to understand VZV pathogenesis at the level of gene function e.g., to identify gene sequences associated with the ability of the virus to infect PBMC or other target cell of the virus. While it is clearly a longterm objective, such genetic manipulations of VZV could yield a recombinant VZV strain that induced persistent humoral and cell-mediated immunity to VZV without retaining the capacity to infect PBMC and neural cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI020459-11
Application #
3130161
Study Section
Experimental Virology Study Section (EVR)
Project Start
1983-08-01
Project End
1994-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
11
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Zerboni, Leigh; Sung, Phillip; Lee, Gordon et al. (2018) Age-Associated Differences in Infection of Human Skin in the SCID Mouse Model of Varicella-Zoster Virus Pathogenesis. J Virol 92:
Sen, Nandini; Sung, Phillip; Panda, Arjun et al. (2018) Distinctive Roles for Type I and Type II Interferons and Interferon Regulatory Factors in the Host Cell Defense against Varicella-Zoster Virus. J Virol 92:
Sullivan, Nicole L; Reuter-Monslow, Morgan A; Sei, Janet et al. (2018) Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans. J Virol 92:
Oliver, Stefan L; Yang, Edward; Arvin, Ann M (2017) Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection. J Virol 91:
François, Sylvie; Sen, Nandini; Mitton, Bryan et al. (2016) Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. J Virol 90:8686-97
Khalil, Mohamed I; Che, Xibing; Sung, Phillip et al. (2016) Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication. Virology 492:82-91
Oliver, Stefan L; Yang, Edward; Arvin, Ann M (2016) Varicella-Zoster Virus Glycoproteins: Entry, Replication, and Pathogenesis. Curr Clin Microbiol Rep 3:204-215
Sen, Nandini; Arvin, Ann M (2016) Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells. J Virol 90:3284-7
Sen, Nandini; Mukherjee, Gourab; Arvin, Ann M (2015) Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus. Methods 90:85-94

Showing the most recent 10 out of 113 publications